Paul Chasan
la Jolla, CANPI 1477871127
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (50.7%), gifts and consulting fees — rather than concentrated in one kind of arrangement. AbbVie accounts for 93.1% of it on its own, with 12 other manufacturers making up the rest. Reporting peaked in 2019 at $18,457 and has fallen 97.0% since, to $547 in 2025.
Across 156 payments — averaging $408.29 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$59K
- Merz North America, Inc.$3K
- TELA Bio, Inc.$433
- Sientra, Inc.$389
- Galderma Laboratories, L.p.$248
- Mentor Worldwide LLC$137
- plus $317 from 7 others
Across 2 payments — averaging $325.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AbbVie$650
What the payments were for
- Consulting fees$7,72212%
- Speaking & faculty fees$32,26751%
- Food & beverage$6,54410%
- Education$820%
- Gifts$17,07827%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 104 | $59,297 |
| Merz North America, Inc. | 23 | $2,872 |
| TELA Bio, Inc. | 6 | $433 |
| Sientra, Inc. | 5 | $389 |
| Galderma Laboratories, L.p. | 4 | $248 |
| Mentor Worldwide LLC | 1 | $137 |
| Integra Lifesciences Corporation | 5 | $111 |
| Revance Therapeutics, Inc. | 3 | $83 |
| Vertex | 1 | $32 |
| Stryker | 1 | $31 |
| Kls-martin L.p. | 1 | $24 |
| Motiva USA, LLC | 1 | $18 |
| Pacira Pharmaceuticals Incorporated | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 12 | $78 |
| Ondansetron OdtOndansetron | 11 | $46 |
| Cephalexin | 13 | $42 |
Paid to pharmacies, not to this prescriber.
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.